Companies Dominating the Dravet Syndrome Treatment Landscape
- AbbVie Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cadila Healthcare Ltd.
- Encoded Therapeutics Inc.
- Epygenix Therapeutics Inc.
- H Lundbeck AS
- Jazz Pharmaceuticals Plc
- Johnson and Johnson
- Lupin Ltd.
- PTC Therapeutics Inc.
- Stoke Therapeutics Inc.
- Supernus Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of dravet syndrome is evaluated at USD 680.28 million.
The dravet syndrome market size was over USD 631.44 million in 2024 and is poised to exceed USD 1.95 billion by 2037, witnessing over 9.1% CAGR during the forecast period i.e., between 2025-2037. Increasing child population and growing research & development will drive the market growth.
North America industry is predicted to dominate majority revenue share of 39% by 2037, impelled by rising spending in healthcare sector in the region.
The major players in the market are Cadila Healthcare Ltd., Encoded Therapeutics Inc., Epygenix Therapeutics Inc., H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., PTC Therapeutics Inc., Stoke Therapeutics Inc.
